

=> d all

L19 ANSWER 1 OF 1 CAPLUS COPYRIGHT 1998 ACS
AN 1996:676097 CAPLUS
DN 125:294034
TI Hepatocyte growth factor for prevention or treatment of intestinal diseases
IN Ishii, Takehisa
PA Mitsubishi Chem Corp, Japan
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
PI JP 08231418 A2 960910 Heisei
AI JP 95-37366 950224
DT Patent
LA Japanese
IC ICM A61K038-22
CC 2-10 (Mammalian Hormones)
Section cross-reference(s): 1
AB Hepatocyte growth factor having mol. wt. of 6000-92,000 (SDS-PAGE under nonreducing conditions), activating liver parenchyma cells, labile to heat treatment at 80.degree. for 10 min or treatment with trypsin or chymotrypsin, and showing strong affinity to heparin is useful for the prevention or treatment of intestinal diseases such as ulcerous colitis and inflammatory colitis. In vitro expts. indicated that hepatocyte growth factor promotes the intestinal cell proliferation, intestinal mobility and organ formation activity.
ST hepatocyte growth factor intestine disease; colitis treatment
hepatocyte growth factor
IT Inflammation inhibitors
Intestine, disease
(hepatocyte growth factor for prevention or treatment of intestinal diseases)
IT Intestine, disease
(colitis, ulcerous or inflammatory; hepatocyte growth factor for prevention or treatment of intestinal diseases)
IT Lymphokines and Cytokines
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(scatter factor, hepatocyte growth factor for prevention or treatment of intestinal diseases)